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panded Polytetrafluoroethylene/Nitinol Self-Expanding Stent Graft
vs Prosthetic Femoral-Popliteal Bypass in the Treatment of Superficial
Femoral Artery Occlusive Disease
Karen McQuade, Dennis R. Gable, Greg J. Pearl, and Brian Theune, From
the Baylor University Medical Center. Dallas, Tex
Background: This randomized prospective study compared the treat-
ment of superficial femoral artery occlusive disease percutaneously with an
expanded polytetrafluoroethylene (ePTFE)/nitinol self-expanding stent
graft vs surgical femoral to above knee popliteal artery bypass with synthetic
graft material.
Methods: One hundred limbs in 86 patients with superficial femoral
artery occlusive disease were evaluated fromMarch 2004 toMay 2005. Patient
symptoms included claudication and limb-threatening ischemiawith orwithout
tissue loss. Trans-Atlantic InterSociety Consensus (TASC II) A (n 18), B (n
 56), C (n  11), and D (n  15) lesions were included. Patients were
randomized prospectively into a percutaneous treatment group (group A; n
50) with angioplasty and placement of one or more stent grafts or a surgical
treatment group (groupB; n50)with a femoral to above knee popliteal artery
bypass using synthetic conduit (Dacron or ePTFE). Patients were followed up
for 48 months. Follow-up evaluation included clinical assessment, physical
examination, ankle-brachial indices (ABI), and color flow duplex ultrasound
imaging at 3, 6, 9, 12, 18, 24, 36, and 48 months.
Results: Mean (standard deviation) total lesion length of the treated
arterial segment in the stent graft group was 25.6 (15) cm. The stent graft
group demonstrated a primary patency of 72%, 63%, 63%, and 59% with a
secondary patency of 83%, 74%, 74%, and 74% at 12, 24, 36, and 48months,
respectively. The surgical femoral-popliteal group demonstrated a primary
patency of 76%, 63%, 63%, and 58%, with a secondary patency of 86%, 76%,
76%, and 71% at 12, 24, 36, and 48 months, respectively. No statistical
difference was found between the two groups with respect to primary (P 
.807) or secondary patency (P  .891). A statistical difference was found in
limb salvage and amputation-free survival at 48 months, however, with limb
salvage rates of 98% in the stent graft group and 84% in the surgical group (P
 .039).
Conclusions: Management of superficial femoral artery occlusive dis-
ease with percutaneous stent grafts exhibits similar primary patency at 4-year
(48-month) follow-up compared with conventional femoral-popliteal artery
bypass grafting with synthetic conduit. This treatment method may offer an
alternative to treatment of the superficial femoral artery segment for revas-
cularization when a prosthetic bypass is being considered or when autolo-
gous conduit is unavailable.
Restenosis Following Carotid Endarterectomy in a Multicenter Re-
gional Registry
Philip P. Goodney,1 Brian W. Nolan,1 Jens Eldrup-Jorgensen,2 Andrew C.
Stanley,3 Donald S. Likosky,1 and Jack L. Cronenwett,1 From Dartmouth-
Hitchcock, Lebanon, NH1; Maine Medical Center, Portland, Me2; and
Fletcher Allen Healthcare, University of Vermont, Burlington, Vt.
3 Lebanon, NH; Portland, Me; and Burlington, Vt
Background: Level I evidence has shown that patch angioplasty, when
used during conventional carotid endarterectomy (CEA), results in lower
Fig 1. Rate of patch angioplasty after conventional carotid end-
arterectomy.rates of restenosis. However, it remains unclear how this information has
affected practice patterns and outcomes in real-world vascular surgery set-
tings.
Methods:Within the Vascular Study Group of NorthernNewEngland
(VSGNNE), we studied 2934 patients undergoing 3118 first-time CEA
between January 1, 2003, and December 31, 2007. Rates of restenosis
(defined as on duplex ultrasound imaging at 1-year follow-up) were calcu-
lated using life-table analysis. Cox proportional-hazardsmodels were used to
identify multivariate predictors of restenosis.
Results:Overall, 2724 patients (87%) underwent conventional CEA, and
394 (13%) underwent eversion CEA. The proportion conventional CEAs
performedwith patching increased over time, from87% in 2003 to 95% in 2008
(P  .001; Fig 1). Concomitantly, the use of eversion CEA declined signifi-
cantly, from 17% of all cases in 2003 to 8% of all cases in 2007 (P  .001).
Restenosis occurred in 313 patients (10%) but most commonly was noncritical
in nature: 7.6% had a 50% to 80% restenosis, 1.8% had an 80% to 99% restenosis,
and 0.5% had an occlusion.Univariate analyses showed significant differences in
critical (80% to 99%) restenosis by procedure type (1.1 % in conventional CEA,
6.6% in eversion CEA, P  .002), the year of procedure (3% in 2003, 0.6% in
2008, P  .03), and use of patching (2.9% no patch, 1.0% with patch, P 
.008). Among patients undergoing conventional CEA, multivariate analysis
demonstrated that surgery in a hospital with a high restenosis rate in prior years
(hazard ratio [HR], 2.6; 95% confidence interval [CI], 1.4-4.9), absence of
patching (HR, 2.7; 95% CI, 1.3-5.4), and contralateral 80% internal carotid
artery stenosis (HR, 3.2; 95% CI 1.5-7.0) were independently associated with a
higher risk of an 80% to 99% restenosis at 1 year (Fig 2). Reintervention was
performed1 year in 13 of 58 patients with 80% to 99% restenosis, consisting
of three reoperations and 10 carotid artery stent procedures. Of the 16 patients
with a carotid occlusion1 year, one patient sustained a major stroke and one
a minor stroke.
Conclusions: In our region, clinically significant restenosis after CEA
fell slightly over time, associated with an increase in patching and a decline in
the use of eversion endarterectomy. Other factors, such as the degree of
contralateral stenosis, also affected restenosis rates after CEA. Quality im-
provement efforts aimed toward increasing the use of patch angioplasty may
offer an opportunity to limit restenosis after CEA.
Subintimal Angioplasty of Chronic Total Occlusion in Iliac Arteries: A
Safe and Durable Option
Brian L. Chen, Harry R. Holt, Jarrod D. Day, Christopher L. Stout, William
Veale, Gordon K. Stokes, and Jean M. Panneton, From the Division of
Vascular Surgery, Eastern Virginia Medical School. Norfolk, Va
Background: Aortofemoral bypass has traditionally been the interven-
tion of choice for chronic total occlusions (CTO) of iliac arteries. However,
it is associated with significant mortality and morbidity, making this proce-
dure prohibitive in high-risk patients. To reduce procedural risk, many have
used subintimal angioplasty (SIA) for femoropopliteal CTO, but few have
extended this endovascular technique to treating iliac CTOs.We present out
experience with 101 successful SIAs in iliac artery CTO.
Methods: A retrospective review of consecutive patients with iliac
artery CTO treated with SIA from June 2000 to July 2009 was completed.
Fig 2. Restenosis rate after carotid endarterectomy in the Vascu-
lar Study Group of Northern New England, 2003-2007.Demographic, risk factor data, and procedural data were obtained. Primary
and secondary patency was determined by Kaplan-Meier survival analysis.
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tation, and death were also recorded.
Results: A total of 122 patients underwent an attempted SIA of an iliac
CTO, with success in 101 (83%). Technical failure was due to the inability to
re-enter the lumen in all cases. Mean age of patients was 65 years (range,
42-90 years), with a male/female ratio of 3:2. Clinical profile for this cohort
was remarkable for a high percentage of coronary artery disease (58%),
diabetes (40%), and end-stage renal disease (13%); 32 (32%) of these patients
were considered nonsurgical candidates. Indications for iliac SIA were severe
claudication in 64 (64%) and critical limb ischemia in 37 (36%). Ninety
patients underwent percutaneous SIA, and 11 patients underwent a hybrid
procedure: SIA with an ipsilateral femoral endarterectomy or femoral-to-
distal bypass. Lesion distribution was 69 common iliac arteries and 61
external iliac arteries. In 20 patients, a more distal lumen re-entry was
achieved into the superficial femoral artery (n 16) or the popliteal artery (n
 4). Stents were deployed in 82 patients (81%), with an average of 1.1
stents used (range, 0-3). True lumen re-entry was achieved with an assist
device in 15 patients (15%). Mean ankle-brachial index (ABI) was 0.52
(range, 0.12-0.95) preoperatively and 0.76 (range, 0.36-1.30) postopera-
tively.Mean ABI at last follow-up was 0.80 (range, 0.36-1.20). Claudication
improvement was documented in 46 (72%). At 1 and 2 years, primary
patency was 80% and 69%, respectively, secondary patency was 92% and 86%,
respectively, and limb salvage was 99% and 97%, respectively. The ulcers in
nine of 12 patients healed after SIA. Procedural 30-day mortality rate was 1%
(1 of 101); one patient died from an intraoperative rupture of a proximal
common iliac aneurysm. Survival rate was 93% and 65% at 1 and 4 years,
respectively, reflecting the poor health status of this cohort.
Conclusions: This study demonstrates that SIA of iliac CTO is feasible
and can be performed safely and effectively, even in high-risk patients.
Excellent patency and limb salvage rates can be achieved. In our experience,
the safety and durability of SIA makes it an attractive first-line therapy for
iliac occlusive disease.
Thoracic Endovascular Aortic Repair Broadens Treatment Eligibility
and Decreases Overall Mortality in Traumatic Thoracic Aortic Injury
Michael S. Hong, Robert J. Feezor, W. Anthony Lee, and Peter R. Nelson,
From the University of Florida. Gainesville, Fla
Background:Aortic injury is the second leading cause of death in trauma.
Thoracic endovascular aortic repair (TEVAR) has recently been applied to
traumatic aortic injuries as a minimally invasive alternative to open surgery and
is gaining favor as the preferred treatment option. We sought to determine the
effect of TEVAR on national trends in the management of aortic trauma.
Methods: The Nationwide Inpatient Sample (NIS) was queried from the
years 2001 to 2007, and patients diagnosed with injury to the thoracic aorta
were selected using code 901.0 of the International Classification of Diseases
(9th ed). Patients were evaluated based on open surgical repair, TEVAR, or
nonoperative management, before and after widespread adoption of TEVAR
for aortic trauma (2001 to 2005 and 2006 to 2007; Fig). Analyses with 2 and
t tests were performed to determine trends in the use of open surgery, use of
TEVAR, inpatient death, major complications, and length of stay.
Results: The NIS documented an average of 241 inpatient admissions
with a diagnosis of thoracic aortic trauma per year, corresponding to an
estimated 1180 yearly admissions in the United States. A comparison of the
time periods 2001 to 2005 and 2006 to 2007 showed a significant increase in
TEVAR (P .001) with a concomitant decrease in open repair (P .001) in
2006 to 2007. The overall number of interventions significantly increased (P
● Rates of open surgical repair, thoracic endovascular aneurysm
repair (TEVAR), or nonoperative management, before and after
widespread adoption of TEVAR for aortic trauma.001). The overall mortality rate significantly decreased (24.8% vs 18.7%, P 
.006), corresponding to a trend toward improved survival in the nonoperative
group (27.8% vs 25.0%, P .053). There was no improvement in open repair
mortality rates between the two time periods. The TEVAR group had a
significantly higher percentage of patients with intra-abdominal injuries (85% vs
70%,P .002), and hemothorax (48% vs 36%,P .038) than the open surgery
group; however, there were no differences in the number of closed head injuries
or major orthopedic fractures. The open surgery group had higher rates of
postoperative respiratory failure (61%vs 50%,P .047), but nodifferenceswere
seen in paraplegia or renal failure. Overall in-hospital mortality was 22.9%:
26.3% among the nonoperative group, 12.2%with open repair, and 10.4%with
TEVAR. The difference in mortality between open repair and TEVAR was not
significant. Length of stay was 15 days in the TEVAR group compared 22 days
with open repair (P .001).
Conclusions: Among patients with aortic trauma, the use of TEVAR has
decreased the rate of open aortic repair and increased the overall number of
patients receiving intervention. Since the wider adoption of TEVAR in 2006,
fewer patients are managed nonoperatively, and overall survival has improved.
There was no difference in mortality between TEVAR and open repair in our
study, which may reflect more aggressive treatment in the TEVAR group of
those who previously would not have been offered intervention due to injury
severity. Evidence suggests that TEVAR has made a significant impact in the
management of this trauma population nationally, although more studies are
indicated to further clarify its role in traumatic aortic disruption.
Does the Current Reimbursement System Make Sense? A Real-World
Analysis of Payment Per Unit Time in a Maryland Vascular Practice
John D. Martin, Patricia B. Warble, Jerry E. Mapes, Linda L. Weiss, Toni B.
Schiller, Kimberly A. England, Louise A. Hanson, Jon A. Altschuler, Jon A.
Hupp, and Stephen F. Stanziale, From the Anne Arundel Medical Center.
Annapolis, Md
Background: In 1992, the Centers for Medicare and Medicaid Services
instituted the Resource Based Relative Value Scale (RBRVS) system to deter-
mine physician reimbursement, incorporating three components of physician
services: physician work, practice expense, and liability insurance. The relative
value units (RVU) are assigned to eachCurrent Procedural Terminology (CPT)
code and are intended to reflect the time and intensity of work. This RVU is the
core value that determines the “fair” reimbursement for physician work. Does
this system accurately balance the true time it takes for each procedure? The
purpose of this study was to determine how well this system distributes pay-
ments for hospital-based procedures during a 12-month period.
Methods: From July 1, 2008, to June 30, 2009, procedural times for
all vascular interventions (time into room until time out of room) were
recorded. Additionally recorded were 15 minutes for administrative time on
the day of the procedure, each hospital day, and all office visits within the
global period (the total care time). The actual physician’s total fee collected
for each of these procedures was divided by the total care time to determine
the payment per unit time. We did not isolate unbundled codes, but rather
reported the total reimbursement for the entire procedure to more accu-
rately reflect the typical vascular experience.
Results: Data were collected on all 1103 procedures performed during this
period. The analysis excluded 37 patients (35 no payments received, 2 incomplete
times recorded). Carrier distribution was 75%Medicare and 25% private.
Table. Reimbursement per unit time is reflected in the
following chart for each of the major procedures:
Procedure Number
OR time
(hrs)
Post-op
days
Consult
time (hrs)
Reimbursement
Total$ $/h
Aortic bypass 15 65.9 52 22.75 31,809 359
Aortic endograft 25 66.9 36 27.25 55,807 593
Abdominal endovascular 39 62.4 0 9.75 44,200 612
Carotid endarterectomy 118 242.9 150 116.00 137,559 383
Carotid stent 20 27.4 20 13.25 26,419 650
Cerebral arteriography 7 8.2 0 1.75 4867 487
Bypass graft revision
Open 6 14.8 15 7.25 8439 382
Endo 5 6.1 0 1.25 4523 617
LE bypass 45 166.5 145 74.00 70,211 292
L. extremity endarterectomy 23 54.4 34 23.75 38,452 492
L. extremity endovascular 179 270.7 0 44.75 192,139 609
L. extremity thrombectomy 13 32.1 57 23.00 20,166 366
Dialysis graft revision
Open 46 73.5 56 39.75 32,019 283
Endo 119 125.5 4 35.00 85,725 534
Dialysis access 76 127.7 15 56.25 49,328 268
L. extremity arteriography 106 117.4 0 26.50 52,310 364
Fistulogram 12 9,7 0 3.00 3261 245
Caval filter insert/remove 22 17.3 39 15.50 19,891 606
L. extremity venous 30 34.8 0 15.25 19,498 389
L. extremity amputation 47 65.5 244 90.25 34,686 223
Visceral endovascular 32 43.3 0 8.00 35,020 682
